Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • bidimensional product  (1)
  • phase II trial  (1)
  • surgery  (1)
  • 1
    Electronic Resource
    Electronic Resource
    A Phase II Study of Preradiation Chemotherapy Followed by External Beam Radiotherapy for the Treatment of Patients with Newly Diagnosed Glioblastoma Multiforme: An Eastern Cooperative Oncology Group Study (E2393) (2000)
    Springer
    Journal of neuro-oncology 47 (2000), S. 145-152 
    Details
    ISSN: 1573-7373
    Keywords: glioblastoma multiforme ; chemotherapy ; radiotherapy ; phase II trial
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Recent publications support the use of preradiation chemotherapy in the treatment of selected primary brain tumors. In the pediatric population, this treatment strategy often delays radiotherapy and may improve the outcome in patients. This manuscript describes the use of a preradiation chemotherapy approach for adult patients with newly diagnosed glioblastoma multiforme. The main objective of this trial was to determine the feasibility of delivering up to 3 monthly cycles of a 72 h continuous simultaneous intravenous infusion of BCNU (40 mg/m2/day) and cisplatin (40 mg/m2/day). Patients were evaluated for tumor response or progression after each cycle. Following the completion of the chemotherapy treatments or evidence of tumor progression, patients underwent external beam radiotherapy. A dose of 45 Gy was delivered to the pretreatment tumor volume plus surrounding edema and a margin of 3.0 cm. An additional 14.4 Gy was delivered to the preoperative volume plus a 2 cm margin. Fifty patients were enrolled, 47 were eligible and analyzable. Overall, 79% of patients were able to complete at least 2 cycles of treatment, exceeding the predefined measure of feasibility. One patient achieved a complete response, 10 patients a partial response and 18 patients had stable disease at completion of the chemotherapy treatments. Twenty-four patients experienced grade 4 toxicity, mostly hematologic. All patients were able to undergo radiotherapy following chemotherapy. These results indicate that a preradiation strategy is feasible. Although responses to the chemotherapy were seen, a phase III trial is needed to determine whether this approach provides an advantage over standard treatment; such a phase III trial has been undertaken by ECOG.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1006402123397
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Recurrent Malignant Gliomas Treated with Radiosurgery (1999)
    Springer
    Journal of radiosurgery 2 (1999), S. 119-125 
    Details
    ISSN: 1573-8752
    Keywords: Radiosurgery ; malignant glioma ; surgery ; brachytherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The inability to control malignant glioma results in a high incidence of local failure and poor survival. Focal therapy such as radiosurgery permits delivery of a high dose of radiation with moderate toxicity. This report summarizes the outcome of patients with recurrent malignant glioma treated with radiosurgery at University of Wisconsin Hospital, between January 1989 and December 1997, when 30 patients were treated radiosurgically. All patients had undergone and failed external beam radiotherapy (median dose of 59.4 Gy) prior to radiosurgery. All recurrences were detected by clinical deterioration and confirmed by radiographic progression. No patient was treated for radiographic progression only in the context of a screening protocol. Eight out of 30 patients underwent subtotal resection prior to radiosurgery and 3 received chemotherapy along with radiosurgery. Radiosurgery was delivered in a single fraction using a modified linear accelerator. The median tumor volume was 7.2 cm3 (range 0.42–35.1 cm3) and the median minimal tumor dose was 12 Gy at the 50–80% isodose line. Median follow-up is 70 months. The median overall survival is 8 months; the 1- and 2-year survival rates are 20% and 9%, respectively. For patients with an initial diagnosis of non-glioblastoma, the median survival is 11 months and for those with glioblastoma the median survival is 7 months. The median progression-free survival is 4 months for the entire cohort, 5 months for nonglioblastoma, and 3 months for glioblastoma. The 1-year actuarial reoperation rate after radio-surgery is 7.6%. Radiosurgery for recurrent malignant glioma may improve short-term survival for selected patients with a lower reoperation rate than brachytherapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1022969211720
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Comparison of Methods for Response Analysis of Central Nervous System Neoplasms (1999)
    Springer
    Journal of radiosurgery 2 (1999), S. 153-161 
    Details
    ISSN: 1573-8752
    Keywords: Brain metastases ; glioblastoma multiforme ; bidimensional product ; tridimensional product ; volume
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The primary objective of this study is to determine whether the conventionally utilized “gold standard” methodology of bidimensional product is reproducible for the purpose of ascertaining response to treatment in CNS neoplasms. Secondary objectives include testing of volumetric methods for response analysis and examining the variability due to tumor pathology, observer, and other factors. Twenty-five patients with brain metastases (evaluated by serial CT) and 16 patients with glioblastoma multiforme (evaluated by serial MRI) were the subjects of this study. The images were reviewed independently by 5 observers and analyzed subjectively, bidimensionally, tridimensionally, and volumetrically, using an NIH-developed software tool, NIH Image. Volume proved to be the most precise measurement technique. Interobserver reproducibility for volume measurements was superior to that of all other methods tested, with the range of correlation coefficients being: bidimensional product = .88–.98, area = .94–.99, tridimensional product = .75–.99, and volume = .96–1.00. Misclassification in tumor response rates was lowest for volume measurements (mean = .23, range = .20–.27) and highest for bidimensional product (mean = .39, range = .34–.44). Volume derived from CT or MRI is a more precise measure of tumor size, yielding consistently lower misclassification rates than traditional bidimensional product or cross-sectional area. This superiority holds irrespective of pathology, tumor size, or observer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1022970730375
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...